Want to see LTESF full AI Analyst Report?
LEET (LTESF) Risk Analysis
Risk Overview Q4, 2023
Source: the company's latest filing for the period ended Dec 31, 2023, filed Apr 15, 2024
Risk Change Over Time
- Share Price & Shareholder Rights - Risk 1The market price of our common stock is volatile and may continue to fluctuate significantly, which could result in substantial losses for stockholders.
The market price of our common stock has been, and may continue to be, subject to significant fluctuations. Among the factors that may cause the market price of our common stock to fluctuate are the risks described in this "Risk Factors" section and other factors, including: - fluctuations in our operating results or the operating results of our competitors; - changes in estimates of our financial results or recommendations by securities analysts; - variance in our financial performance from the expectations of securities analysts; - changes in the estimates of the future size and growth rate of our markets; - changes in accounting principles or changes in interpretations of existing principles, which could affect our financial results; - conditions and trends in the markets we currently serve or which we intend to target with our product candidates; - changes in general economic, industry and market conditions; - the impact of the COVID-19 impact, including the magnitude, severity, duration, and uncertainty of the downturn in the domestic and global economies and financial markets; - success of competitive products and services; - changes in market valuations or earnings of our competitors; - announcements of significant new products, contracts, acquisitions or strategic alliances by us or our competitors; - our continuing ability to list our securities on an established market or exchange; - the timing and outcome of regulatory reviews and approvals of our products; - the commencement or outcome of litigation involving our company, our general industry or both; - changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; - actual or expected sales of our common stock by the holders of our common stock; and - the trading volume of our common stock. In addition, the financial markets may experience a loss of investor confidence or otherwise experience continued volatility and deterioration due to the COVID-19 pandemic. A loss of investor confidence may result in extreme price and volume fluctuations in our common stock that are unrelated or disproportionate to the operating performance of our business, our financial condition, or results of operations, which may materially harm the market price of our common stock and result in substantial losses for stockholders.
- Share Price & Shareholder Rights - Risk 2Future sales of our common stock could cause dilution, and the sale of such common stock, or the perception that such sales may occur, could cause the price of our stock to decline.
Sales of additional shares of our common stock, as well as securities convertible into or exercisable for common stock, could result in substantial dilution to our stockholders and cause the market price of our common stock to decline. An aggregate of 152,899,640 shares of common stock were outstanding as of April 15, 2022. There are no outstanding options or warrants to purchase shares of our common stock. A substantial majority of the outstanding shares of our common stock are freely tradable without restriction or further registration under the Securities Act. We may sell additional shares of common stock, as well as securities convertible into or exercisable for common stock, in subsequent public or private offerings. We may also issue additional shares of common stock, as well as securities convertible into or exercisable for common stock, to finance future acquisitions. We will need to raise additional capital in order to initiate or complete additional development activities for all of our product candidates, or to pursue additional disease indications for our product candidates, and this may require us to issue a substantial amount of securities (including common stock as well as securities convertible into or exercisable for common stock). There can be no assurance that our capital raising efforts will be able to attract the capital needed to execute on our business plan and sustain our operations. Moreover, we cannot predict the size of future issuances of our common stock, as well as securities convertible into or exercisable for common stock, or the effect, if any, that future issuances and sales of our securities will have on the market price of our common stock. Sales of substantial amounts of our common stock, as well as securities convertible into or exercisable for common stock, including shares issued in connection with an acquisition or securing funds to complete any clinical trial plans, or the perception that such sales could occur, may result in substantial dilution and may adversely affect prevailing market prices for our common stock.
- Corporate Activity and Growth - Risk 3We are an early-stage company operating in a newly developing industry with limited resources.
The Company officially launched its commercial service (Matchroom) in Malaysia in January 2019. Because the Company has a limited operating history, you should consider and evaluate our operating prospects in light of the risks and uncertainties frequently encountered by early-stage companies in rapidly evolving markets. These risks include: - That we may not have sufficient capital to achieve our growth strategy;- That we may not develop our product and service offerings in a manner that enables us to be profitable and meet our customers' requirements;- That our growth strategy may not be successful; and - That fluctuations in our operating results will be significant relative to our revenues These risks are described in more detail below. Our future growth will depend substantially on our ability to address these, and the other risks described in this section. If we do not successfully address these risks, our business could be significantly harmed.
Risk Highlights Q4, 2023
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 16
- Share Price & Shareholder Rights - Risk 1The market price of our common stock is volatile and may continue to fluctuate significantly, which could result in substantial losses for stockholders.
The market price of our common stock has been, and may continue to be, subject to significant fluctuations. Among the factors that may cause the market price of our common stock to fluctuate are the risks described in this "Risk Factors" section and other factors, including: - fluctuations in our operating results or the operating results of our competitors; - changes in estimates of our financial results or recommendations by securities analysts; - variance in our financial performance from the expectations of securities analysts; - changes in the estimates of the future size and growth rate of our markets; - changes in accounting principles or changes in interpretations of existing principles, which could affect our financial results; - conditions and trends in the markets we currently serve or which we intend to target with our product candidates; - changes in general economic, industry and market conditions; - the impact of the COVID-19 impact, including the magnitude, severity, duration, and uncertainty of the downturn in the domestic and global economies and financial markets; - success of competitive products and services; - changes in market valuations or earnings of our competitors; - announcements of significant new products, contracts, acquisitions or strategic alliances by us or our competitors; - our continuing ability to list our securities on an established market or exchange; - the timing and outcome of regulatory reviews and approvals of our products; - the commencement or outcome of litigation involving our company, our general industry or both; - changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; - actual or expected sales of our common stock by the holders of our common stock; and - the trading volume of our common stock. In addition, the financial markets may experience a loss of investor confidence or otherwise experience continued volatility and deterioration due to the COVID-19 pandemic. A loss of investor confidence may result in extreme price and volume fluctuations in our common stock that are unrelated or disproportionate to the operating performance of our business, our financial condition, or results of operations, which may materially harm the market price of our common stock and result in substantial losses for stockholders.
- Share Price & Shareholder Rights - Risk 2Future sales of our common stock could cause dilution, and the sale of such common stock, or the perception that such sales may occur, could cause the price of our stock to decline.
Sales of additional shares of our common stock, as well as securities convertible into or exercisable for common stock, could result in substantial dilution to our stockholders and cause the market price of our common stock to decline. An aggregate of 151,096,262 shares of common stock were outstanding as of August 4, 2023. There are no outstanding options or warrants to purchase shares of our common stock. A substantial majority of the outstanding shares of our common stock are freely tradable without restriction or further registration under the Securities Act. We may sell additional shares of common stock, as well as securities convertible into or exercisable for common stock, in subsequent public or private offerings. We may also issue additional shares of common stock, as well as securities convertible into or exercisable for common stock, to finance future acquisitions. We will need to raise additional capital in order to initiate or complete additional development activities for all of our product candidates, or to pursue additional disease indications for our product candidates, and this may require us to issue a substantial amount of securities (including common stock as well as securities convertible into or exercisable for common stock). There can be no assurance that our capital raising efforts will be able to attract the capital needed to execute on our business plan and sustain our operations. Moreover, we cannot predict the size of future issuances of our common stock, as well as securities convertible into or exercisable for common stock, or the effect, if any, that future issuances and sales of our securities will have on the market price of our common stock. Sales of substantial amounts of our common stock, as well as securities convertible into or exercisable for common stock, including shares issued in connection with an acquisition or securing funds to complete any clinical trial plans, or the perception that such sales could occur, may result in substantial dilution and may adversely affect prevailing market prices for our common stock.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.